MediWound (NASDAQ:MDWD) Issues Quarterly Earnings Results

MediWound (NASDAQ:MDWD) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.42, RTT News reports. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. During the same period last year, the business posted ($0.07) EPS.

Here are the key takeaways from MediWound’s conference call:

• EscharEx remains the company’s main development priority, but the VALUE Phase III study has been pushed back by one quarter, with enrollment now expected to finish by the end of Q1 2027. Management said the delay was driven by operational issues in Europe and the burden of frequent wound assessments, not by safety or efficacy concerns.
• The company said its EscharEx collaboration network has expanded to include nearly all major advanced wound care players, now adding Medline. This broader industry involvement was presented as external validation of EscharEx and could support future commercialization and additional studies in DFU and pressure ulcers.
• NexoBrid continued to gain commercial and strategic traction, with Vericel reporting growth in ordering centers and total orders in the U.S. burn market. MediWound also highlighted a new 10-year BARDA contract worth up to $197 million, with procurement and development expected to begin in the second half of 2026.
• First-quarter 2026 revenue fell to $1.5 million from $4.0 million a year earlier, mainly because of the timing of BARDA-related revenue and shipment delays tied to regional conflict. The quarter also reflected higher R&D spending on the EscharEx VALUE study, contributing to a wider operating loss.
• Management reaffirmed full-year 2026 revenue guidance of $24 million to $26 million, expecting a second-half weighted ramp from government-related development services and procurement. The company said it is working through EMA pre-audit modifications at its expanded manufacturing facility and expects those activities to be completed in the second half of 2026.

MediWound Stock Performance

NASDAQ MDWD opened at $15.39 on Wednesday. MediWound has a one year low of $14.90 and a one year high of $22.50. The stock has a 50-day moving average of $16.79 and a 200 day moving average of $17.51. The company has a market capitalization of $197.77 million, a price-to-earnings ratio of -7.64 and a beta of 0.21.

Institutional Trading of MediWound

Several hedge funds have recently made changes to their positions in MDWD. LPL Financial LLC lifted its position in MediWound by 27.4% in the fourth quarter. LPL Financial LLC now owns 21,875 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 4,709 shares during the last quarter. Wells Fargo & Company MN grew its holdings in MediWound by 35.7% during the 4th quarter. Wells Fargo & Company MN now owns 20,183 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 5,306 shares during the last quarter. Marshall Wace LLP bought a new position in MediWound during the 2nd quarter valued at about $317,000. Jane Street Group LLC purchased a new stake in MediWound in the 2nd quarter worth about $295,000. Finally, Barclays PLC lifted its stake in MediWound by 32.5% in the fourth quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 3,747 shares during the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MediWound currently has an average rating of “Hold” and a consensus price target of $35.00.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.